US 11648307
Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11648307 (Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy) held by The Board of Regents of the University of Texas System expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K35/15, A61K39/395